KOSMAS THERAPEUTICS

Currently, KOSMAS is the only company producing Trilytes in a format that combines "dual-targeting" of the cancer cell with an active engagement of killer cells, which promises to become a leading strategy for cancer therapy... Our innovative products go beyond targeted agents and killer cell-mediated therapies. We have developed a patent-protected technology for the design of Trilyte molecules with more effective targeting of cancer stem cells and greater anti-cancer efficacy than competing agents... Our team of dedicated scientists, physicians and thought-leaders have decades of experience in cancer biology, pathogenetics, immunology and the design of antibody-derived recombinant proteins. It is our primary goal to advance KT1 to the clinic for currently unmet needs of patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), and we have the team and technology to do so.